Cancer and vaccine therapy. 3d illustration

...

Hannah Millington

By Hannah Millington

Health Reporter

0

Share

Newsweek is a Trust Project member

See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.


A vaccine using tiny particles has been shown to effectively prevent melanoma, pancreatic and triple-negative breast cancer in mice.

The study—led from the University of Massachusetts Amherst—demonstrated that 88 percent of vaccinated mice remained tumor-free (depending on the cancer type in question) and the vaccine reduced the cancer’s spread. In some cases, it completely prevented metastasis.

“By engineering these nanoparticles to activate the immune system via multi-pathway activation that combines with cancer-specific antigens, we can prevent tumor growth with remarkable survival rates,” said study author and biomedical engineer professor Prabhani Atukorale in a statement.

Read More on Health

These preventive findings build on previous research that showed that the nanoparticle-based drug can shrink and clear cancer tumors in mice. If developed for people, Atukorale told Newsweek, "a patient would receive the vaccine prophylactically and should remain tumor-free for their life time. This is especially important for people who have a predisposition and increased risk for developing certain cancers."

Cancer tumor and vaccine shown in 3D illustration. | Getty Images/Rasi Bhadramani

...

The first test paired the nanoparticle system with melanoma peptides called an antigen, which triggers an immune response. The formulation activated immune cells called T cells to recognize and attack this type of cancer.

After being exposed to the melanoma cells three weeks later, 80 percent of these “super adjuvant” vaccinated mice stayed tumor-free and survived until the end of the study—250 days in total. Adjuvant refers to a substance that activates the immune system to recognize the antigen.

"Our approach develops a new vaccine by focusing on building a better adjuvant (vaccines need two components, an antigen and an adjuvant). Our adjuvant is a nanoparticle that combines multiple immune activators together, allowing us to 'super-adjuvant' the vaccine," Atukorale explained.

Meanwhile, all of the mice vaccinated with traditional vaccines, non-nanoparticle formulations or unvaccinated mice developed tumors. None survived longer than 35 days. Compared to all mice, the nanoparticle-vaccinated mice were also protected against the spread of cancer to the lungs.

“Metastases across the board is the highest hurdle for cancer,” said Atukorale. “The vast majority of tumor mortality is still due to metastases, and it almost trumps us working in difficult-to-reach cancers, such as melanoma and pancreatic cancer.”

The first test used antigens that matched the type of cancer. But developing antigens tailored to different cancer types requires whole-genome sequencing or complex bioinformatics screenings, the researchers explained. With this in mind, in further tests they used killed cancer cells from the tumor mass, called tumor lysate.

After vaccination with the nanoparticle lysate vaccine, the mice were exposed to either melanoma, of which about 104,960 new cases will be diagnosed in people in the U.S. this year; pancreatic ductal adenocarcinoma, the most common pancreatic cancer; or triple-negative breast cancer cells, which are often more aggressive.

Some 88 percent of mice rejected pancreatic cancer, 75 percent of mice did for breast cancer and 69 percent rejected melanoma tumors. Of these, all remained tumor-free in tests to see if the cancer would spread.

“The tumor-specific T-cell responses that we are able to generate—that is really the key behind the survival benefit,” added study author Griffin Kane in a statement. “There is really intense immune activation when you treat innate immune cells with this formulation, which triggers these cells to present antigens and prime tumor-killing T cells.”

The researchers next plan to extend the technology to a therapeutic vaccine. Further studies will be needed to see how the results translate to humans.

Do you have a tip on a health story that Newsweek should be covering? Do you have a question about the study? Let us know via health@newsweek.com.

Update 10/13/25, 07:38 a.m. ET: This article was updated with additional information and comments from Angela Giaquinto.

References

Kane, G. I., Naylor, T. E., Lusi, E. F., Brassil, M. L., Wigglesworth, K., Dinnell, R. W., Diaz-Infante, M. B., Whiteman, L. M., Lukas, J., Winkler, M., Josh, R., Cerrutti, J., Mori, H., Gallucci, S., Fitzgerald, K. A., & Atukorale, P. U. (2025). Super-adjuvant nanoparticles for platform cancer vaccination. Cell Reports Medicine. https://doi.org/10.1016/j.xcrm.2025.102415

Chibaya, L., DeMarco, K. D., Lusi, C. F., Kane, G. I., Brassil, M. L., Parikh, C. N., Murphy, K. C., Chowdhury, S. R., Li, J., Ma, B., Naylor, T. E., Cerrutti, J., Mori, H., Diaz-Infante, M., Peura, J., Pitarresi, J. R., Zhu, L. J., Fitzgerald, K. A., Atukorale, P. U., & Ruscetti, M. (2024). Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer. Science Translational Medicine, 16(762). https://doi.org/10.1126/scitranslmed.adj9366

View 0 Comments

Request Reprint & Licensing

Submit Correction

View Editorial & AI Guidelines